

**Aerospace Industries Association's  
"What's Next for the International Space Station?"  
August 13, 2009  
Washington, D.C.**

The following are twitter notes taken during the Aerospace Industries Association's "What's Next for the International Space Station?" panel. The notes appear in reverse chronological order, so to read them as they were written, you should start with entry #28 and read to entry #1.

1. End of panel. Charts will be posted on AIA website. Bye!
2. Marion Blakey giving closing remarks. NASA is doing great things now w/ISS.
3. Not concerned w/IP because it's in everybody's interest.
4. Have IP and ITAR been dealt with? Jessup working on this for Earth situations. ITAR is very complex. IP issues are big too.
5. Given 5 more years, there would be more drugs in the FDA pipeline, and a robust NIH research program.
6. Doing things in space is very complex. Using example of moving soyuz capsule from one port to another. Running out of time.
7. NASA doing what they can to provide easy, frequent, inexpensive, and return capabilities. ISS very flexible and can serve many clients.
8. Cost of transport needs to be supported, too. Down mass is another concern. Of 5 possible vehicles, most are 1-way tickets.
9. Access is a major problem. Hard to get standard NIH researcher into ISS mind-set. Congress needs to support access & implementation more.
10. Q&A time! How to publicize ISS availability? Not a lot of attn from pharma industry. Need to have successes, and do more panel events.
11. Solicitation letter of intent due 31 Aug. Talking about some of his microG research on past STS/ISS missions/expeditions.
12. Showing long list of expected research topics for this solicitation, incl convection effects in tumors.
13. New NIH solicitation for Bio Research on ISS (PAR-09-120). Radiation and microG environment research. Ground feasibility & ISS expt phase.
14. Aka MRSA. Using space can cut development timeline and reduce costs. Last spkr, Dr. John Jessup, NIH Cancer Diagnosis Chief.
15. Salmonella vaccine target identified and could be in expt human trials next year. Next program is for methicillin-resistant staph aureus.
16. Talking about vaccine development in space. In microG, can tell why microbial virility which speeds up vaccine development timeline.

17. ave flown on many recent shuttle flights and scheduled to fly on STS128. Onlt comml entity now taking advantage of these opportunities.
18. Microbe and vaccine development programs were best candidates for comm'l development of 3K candidates. 2005 legislation allows comml ISs use
19. ...By developing products in space. New company, but 25 year history w/NASA thru parent company Astrotech.
20. Now showing video of ISS interior (same one on YouTube I think). Next spkr, John Porter, Astrogenetix CEO. Goal: to save lives on Earth...
21. Transition from construction to utilization represents great opportunities. Also as testbed for exploration, ECLSS, GNC, Propulsion, etc.
22. Joy Bryant, Boeing VP for ISS next up. Integration of 5 types of vehicles, 10+ shuttle carriers, 40+ suppliers, 15 nations, 100 expts, etc.
23. Showing great picture of JAXA JEM research lab with exposed porch. Tremendous new capability. Dexter robot also shown.
24. Working w/Academic, industry, govt communities to effectively utilize station. All see potential of iSs and see huge benefits.
25. Panelists: Bill Gerstenmaier NASA AA of SOMD. Talk about future of station post-assembly. 800,000 pounds in orbit. Utilization is crit phase
26. ISS is at a cross-roads and we need to decide what to w/it after 2015. JP Stevens, AIA VP is introducing panelists.
27. Opening remarks by Marion Blakey, AIA. ISS is a true engineering marvel. ISS is a Nat'l Lab available for use by other agencies.
28. Heading to Rayburn Bldg for AIA "What's Next for ISS?" Panel presentation featuring bill Gerstenmaier. Starts at 10am EDT.